Eisai to highlight data from lenvatinib trials for uHCC and RCC

Japanese pharmaceutical company Eisai is planning to present data from the clinical trials of its drug candidate lenvatinib at the European Society for Medical Oncology (ESMO) 2017 Congress to be held in Madrid, Spain, between 8-12 September.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news